{"title":"Reduction of Intraocular Pressure and Glaucoma Progression","authors":"A. Penman, K. W. Crowder, W. Watkins","doi":"10.1093/med/9780190050726.003.0014","DOIUrl":"https://doi.org/10.1093/med/9780190050726.003.0014","url":null,"abstract":"The Early Manifest Glaucoma Trial (EMGT) was a randomized, placebo-controlled clinical trial in patients with newly detected, previously untreated, primary open-angle glaucoma (POAG) to determine whether immediate institution of intraocular pressure (IOP)–lowering therapy reduces the risk of progression compared to delayed treatment or observation. The study showed that IOP-lowering therapy offered a definitive benefit in patients with early glaucoma by delaying progression of glaucomatous optic neuropathy, especially in eyes with higher IOPs (>21 mm Hg) at baseline. Even modest reduction in IOP decreased the risk of progression. However, a large percentage of treated eyes still showed progression during follow-up. The progression of glaucomatous optic neuropathy was highly variable and difficult to predict for an individual patient.","PeriodicalId":443495,"journal":{"name":"50 Studies Every Ophthalmologist Should Know","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115895931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cryotherapy for Retinopathy of Prematurity","authors":"A. Penman, K. W. Crowder, W. Watkins","doi":"10.1093/med/9780190050726.003.0025","DOIUrl":"https://doi.org/10.1093/med/9780190050726.003.0025","url":null,"abstract":"The Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) was a randomized, controlled, interventional clinical trial to determine whether cryotherapy was effective in reducing the unfavorable ocular outcomes from threshold retinopathy of prematurity (ROP). The study showed that at a 3-month assessment, cryotherapy was significantly beneficial for eyes with ROP at a defined threshold level of severity. The findings of the CRYO-ROP study led to the implementation of neonatal screening and peripheral retinal ablation for acute ROP throughout the United States and beyond. Long-term results of CRYO-ROP have also influenced the management of affected patients throughout the remainder of childhood.","PeriodicalId":443495,"journal":{"name":"50 Studies Every Ophthalmologist Should Know","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126290015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prophylaxis of Postoperative Endophthalmitis Following Cataract Surgery","authors":"A. Penman, K. W. Crowder, W. Watkins","doi":"10.1093/med/9780190050726.003.0009","DOIUrl":"https://doi.org/10.1093/med/9780190050726.003.0009","url":null,"abstract":"The European Society of Cataract and Refractive Surgeons (ESCRS) multicenter endophthalmitis study, a randomized, partially masked, clinical trial using a 2 × 2 factorial design, examined the question of whether antibiotic prophylaxis (intracameral cefuroxime and topical perioperative levofloxacin) reduces the incidence of postoperative endophthalmitis after cataract surgery. The study showed that use of intracameral cefuroxime at the end of surgery reduced the occurrence of postoperative endophthalmitis to a level below 0.08%. The authors also recommended that to reduce the risk further, consideration should be given to avoiding the use of silicone intraocular lens optic material and using a scleral tunnel incision rather than a clear corneal incision.","PeriodicalId":443495,"journal":{"name":"50 Studies Every Ophthalmologist Should Know","volume":"82 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127095539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration","authors":"A. Penman, K. W. Crowder, W. Watkins","doi":"10.1093/med/9780190050726.003.0041","DOIUrl":"https://doi.org/10.1093/med/9780190050726.003.0041","url":null,"abstract":"The Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) was a randomized, single-blind, noninferiority trial to evaluate the relative efficacy and safety of intravitreal injections of ranibizumab and bevacizumab (anti–vascular endothelial growth factor (VEGF) agents) for the treatment of neovascular age-related macular degeneration (AMD). At one year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule: bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively, and bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. The comparison between bevacizumab as needed and monthly bevacizumab was inconclusive.","PeriodicalId":443495,"journal":{"name":"50 Studies Every Ophthalmologist Should Know","volume":"126 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130257333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pegaptanib for Neovascular Age-Related Macular Degeneration","authors":"A. Penman, K. W. Crowder, W. Watkins","doi":"10.1093/med/9780190050726.003.0039","DOIUrl":"https://doi.org/10.1093/med/9780190050726.003.0039","url":null,"abstract":"The VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) study comprised two concurrent randomized, double-masked, sham-controlled clinical trials to evaluate the efficacy and safety of a second year of treatment with pegaptanib sodium (an anti-vascular endothelial growth factor [VEGF] agent) in patients with neovascular age-related macular degeneration (AMD). In combined analyses, 88% of patients were re-randomized at week 54, and 89% were assessed at week 102. At week 54, those initially assigned to pegaptanib were re-randomized to continue or discontinue therapy for 48 more weeks (8 injections). Those initially assigned to sham were re-randomized to continue sham, discontinue sham, or receive 1 of 3 pegaptanib doses. The study showed that in patients with a diverse mix of neovascular AMD presentations, treatment with pegaptanib every 6 weeks for 2 years reduced the risk of vision loss regardless of lesion composition or size; this benefit was maintained during year 2.","PeriodicalId":443495,"journal":{"name":"50 Studies Every Ophthalmologist Should Know","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128262383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ranibizumab for Neovascular Age-Related Macular Degeneration","authors":"A. Penman, K. W. Crowder, W. Watkins","doi":"10.1093/med/9780190050726.003.0040","DOIUrl":"https://doi.org/10.1093/med/9780190050726.003.0040","url":null,"abstract":"The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) study was a randomized, double-blind, sham-controlled clinical trial to determine whether intravitreal administration of ranibizumab (an anti-vascular endothelial growth factor [VEGF] agent) prevents vision loss and improves mean visual acuity in patients with minimally classic or occult choroidal neovascularization related to age-related macular degeneration (AMD). Ranibizumab therapy was associated with clinically and statistically significant benefits in visual acuity and the amount of angiographic leakage from choroidal neovascularization during two years of follow-up, with low rates of serious adverse events.","PeriodicalId":443495,"journal":{"name":"50 Studies Every Ophthalmologist Should Know","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126279368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}